Immunology & Autoimmune Deal Benchmarks 2026

The immunology and autoimmune licensing market in 2026 is defined by fierce competition among biologics, JAK inhibitors, and next-generation targeted therapies. Phase 2 monoclonal antibody deals for autoimmune indications carry a median total deal value of $3.0B, with upfront payments ranging from $304M to $919M. SLE/lupus remains one of the most actively pursued indications given the large unmet medical need and limited approved biologics.

Deal structures in autoimmune licensing reflect the breadth of indication expansion potential. Development milestones average $490M, while commercial milestones of $1.1B reward multi-indication lifecycle strategies. The ability to demonstrate differentiation from entrenched TNF and IL-6 therapies is the single largest driver of premium valuations.

Royalty rates for immunology deals settle between 14% and 23.4% at the base tier, with escalation to 27.4% on blockbuster sales. Deals featuring novel mechanisms targeting B-cell depletion, T-regulatory cell modulation, or cytokine-specific pathways command the highest premiums relative to follow-on JAK or IL-targeting agents.